Mu‐Chun Li

565 total citations
22 papers, 402 citations indexed

About

Mu‐Chun Li is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Mu‐Chun Li has authored 22 papers receiving a total of 402 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 7 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in Mu‐Chun Li's work include Cancer, Hypoxia, and Metabolism (3 papers), Cancer Mechanisms and Therapy (2 papers) and Cancer and Skin Lesions (2 papers). Mu‐Chun Li is often cited by papers focused on Cancer, Hypoxia, and Metabolism (3 papers), Cancer Mechanisms and Therapy (2 papers) and Cancer and Skin Lesions (2 papers). Mu‐Chun Li collaborates with scholars based in Taiwan, India and China. Mu‐Chun Li's co-authors include Chiung‐Chyi Shen, Hung-Chuan Pan, Cheng-Yi Chang, Su‐Lan Liao, Chun‐Ying Wu, Hsing‐Pang Hsieh, Yi–Ju Chen, Chia‐Che Chang, Chuan‐Mu Chen and Fu‐Fei Hsu and has published in prestigious journals such as Developmental Cell, Journal of Medicinal Chemistry and Advanced Science.

In The Last Decade

Mu‐Chun Li

18 papers receiving 394 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mu‐Chun Li Taiwan 10 214 68 57 53 51 22 402
Virginia Lotti Italy 10 236 1.1× 62 0.9× 69 1.2× 25 0.5× 78 1.5× 32 561
Abbas Raza United States 13 254 1.2× 93 1.4× 27 0.5× 55 1.0× 89 1.7× 49 647
Isabel Huber‐Ruano Spain 11 166 0.8× 110 1.6× 70 1.2× 28 0.5× 43 0.8× 15 401
Timo Siitonen Finland 16 229 1.1× 131 1.9× 65 1.1× 106 2.0× 74 1.5× 48 572
Leticia Odriozola Spain 11 227 1.1× 48 0.7× 65 1.1× 29 0.5× 23 0.5× 13 389
Juyeun Lee United States 11 106 0.5× 75 1.1× 42 0.7× 20 0.4× 154 3.0× 33 356
Jose Roques United States 10 266 1.2× 108 1.6× 42 0.7× 14 0.3× 55 1.1× 13 397
Diego Arenas‐Aranda Mexico 12 210 1.0× 80 1.2× 21 0.4× 23 0.4× 73 1.4× 26 468
Lin Su China 12 224 1.0× 34 0.5× 23 0.4× 45 0.8× 60 1.2× 33 525
Emeline Cros‐Perrial France 13 211 1.0× 75 1.1× 27 0.5× 12 0.2× 27 0.5× 33 371

Countries citing papers authored by Mu‐Chun Li

Since Specialization
Citations

This map shows the geographic impact of Mu‐Chun Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mu‐Chun Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mu‐Chun Li more than expected).

Fields of papers citing papers by Mu‐Chun Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mu‐Chun Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mu‐Chun Li. The network helps show where Mu‐Chun Li may publish in the future.

Co-authorship network of co-authors of Mu‐Chun Li

This figure shows the co-authorship network connecting the top 25 collaborators of Mu‐Chun Li. A scholar is included among the top collaborators of Mu‐Chun Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mu‐Chun Li. Mu‐Chun Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yang, Chunlin, Huang‐Ju Tu, Tony Eight Lin, et al.. (2025). Identification and Biological Evaluation of a Novel CLK4 Inhibitor Targeting Alternative Splicing in Pancreatic Cancer Using Structure‐Based Virtual Screening. Advanced Science. 12(19). e2416323–e2416323.
2.
Peng, Yi‐Hui, Mu‐Chun Li, Wan-Ching Yen, et al.. (2025). Structure-Based Design of Potent and Selective MerTK Inhibitors by Modulating the Conformation of αC Helix. Journal of Medicinal Chemistry. 68(11). 10877–10896.
3.
Li, Mu‐Chun, Limei Lin, Yi‐Ju Chen, et al.. (2025). KIF2C promotes paclitaxel resistance by depolymerizing polyglutamylated microtubules. Developmental Cell. 60(15). 2097–2113.e8.
4.
HuangFu, Wei‐Chun, Tony Eight Lin, Tzu-Ying Sung, et al.. (2024). Discovery of novel TANK-Binding Kinase 1 (TBK1) inhibitor against pancreatic ductal adenocarcinoma. International Journal of Biological Macromolecules. 283(Pt 1). 137296–137296. 1 indexed citations
5.
Dhayalan, Arunkumar, et al.. (2024). Aldehyde dehydrogenases as drug targets for cancer: SAR and structural biology aspects for inhibitor design. Bioorganic Chemistry. 154. 108019–108019. 3 indexed citations
6.
Li, Mu‐Chun, J. Satyanarayana Reddy, Chih‐Ming Chen, et al.. (2024). Discovery of Dual MER/AXL Kinase Inhibitors as Bifunctional Small Molecules for Inhibiting Tumor Growth and Enhancing Tumor Immune Microenvironment. Journal of Medicinal Chemistry. 67(13). 10906–10927. 3 indexed citations
7.
Li, Mu‐Chun, Mohane Selvaraj Coumar, Shu‐Yu Lin, et al.. (2023). Development of Furanopyrimidine-Based Orally Active Third-Generation EGFR Inhibitors for the Treatment of Non-Small Cell Lung Cancer. Journal of Medicinal Chemistry. 66(4). 2566–2588. 10 indexed citations
8.
Kumari, Monika, Ruei‐Min Lu, Mu‐Chun Li, et al.. (2022). A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies. Journal of Biomedical Science. 29(1). 68–68. 94 indexed citations
9.
10.
Li, Mu‐Chun, Wen‐Hsing Lin, Yu‐Chieh Su, et al.. (2021). Design and synthesis of novel orally selective and type II pan-TRK inhibitors to overcome mutations by property-driven optimization. European Journal of Medicinal Chemistry. 224. 113673–113673. 13 indexed citations
11.
Li, Mu‐Chun & Hsing‐Pang Hsieh. (2020). Tumor‐agnostic inhibitors in oncology: A new phase for precision medicine. Journal of the Chinese Chemical Society. 67(12). 2216–2224. 1 indexed citations
12.
Lin, Shu‐Yu, Mohane Selvaraj Coumar, Fu‐Ming Kuo, et al.. (2020). Drug-like property optimization: Discovery of orally bioavailable quinazoline-based multi-targeted kinase inhibitors. Bioorganic Chemistry. 98. 103689–103689. 9 indexed citations
13.
Blay, Vincent, et al.. (2019). Design of drug-like hepsin inhibitors against prostate cancer and kidney stones. Acta Pharmaceutica Sinica B. 10(7). 1309–1320. 11 indexed citations
14.
Jan, Yee‐Jee, et al.. (2009). A 32‐YEAR‐OLD MAN WITH A FOURTH VENTRICULAR MASS. Brain Pathology. 19(2). 333–336. 3 indexed citations
15.
Chen, Yi–Ju, et al.. (2008). Nuclear Krüppel-like factor 4 expression is associated with human skin squamous cell carcinoma progression and metastasis. Cancer Biology & Therapy. 7(5). 777–782. 70 indexed citations
16.
Chang, Cheng-Yi, et al.. (2005). Prognostic and clinical implication of IL-6 expression in glioblastoma multiforme. Journal of Clinical Neuroscience. 12(8). 930–933. 88 indexed citations
17.
Chang, Tung‐Ming, Ching‐Shiang Chi, Chi‐Ren Tsai, Hsiu-Fen Lee, & Mu‐Chun Li. (2004). Paralytic ileus in MELAS with phenotypic features of MNGIE. Pediatric Neurology. 31(5). 374–377. 24 indexed citations
18.
Li, Mu‐Chun, et al.. (2003). Amyloidosis of medium-sized arteries presenting as perioral mass: A case report. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology. 95(4). 463–466. 8 indexed citations
19.
Cheng, Shao‐Bin, Mu‐Chun Li, Dah‐Cherng Yeh, Tse‐Jia Liu, & Cheng‐Chung Wu. (2002). Adenoid Cystic Carcinoma of the Breast: Report of a Case. 7(2). 109–112. 1 indexed citations
20.
Li, Mu‐Chun, et al.. (2002). The aberrant expression of cytosolic carbonic anhydrase and its clinical significance in human non-small cell lung cancer. Cancer Letters. 188(1-2). 199–205. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Virginia Lotti Breakdown of academic impact, for papers by Abbas Raza Breakdown of academic impact, for papers by Isabel Huber‐Ruano Breakdown of academic impact, for papers by Timo Siitonen Breakdown of academic impact, for papers by Leticia Odriozola Breakdown of academic impact, for papers by Juyeun Lee Breakdown of academic impact, for papers by Jose Roques Breakdown of academic impact, for papers by Diego Arenas‐Aranda Breakdown of academic impact, for papers by Lin Su Breakdown of academic impact, for papers by Emeline Cros‐Perrial
Rankless by CCL
2026